Novartis, UC Berkeley-spawned startup snags $65M to keep key proteins from the cell’s trash can

Vicinitas Therapeutics is developing small molecule drugs that stabilize key proteins, preventing them from going to a cell’s built-in disposal system. The startup, which stems from a research partnership between Novartis and the University of California, Berkeley, has raised $65 million in Series A funding.

Leave a Comment

Your email address will not be published.